IL261134B2 - Preparations and methods for the treatment of sinus diseases and disorders - Google Patents
Preparations and methods for the treatment of sinus diseases and disordersInfo
- Publication number
- IL261134B2 IL261134B2 IL261134A IL26113418A IL261134B2 IL 261134 B2 IL261134 B2 IL 261134B2 IL 261134 A IL261134 A IL 261134A IL 26113418 A IL26113418 A IL 26113418A IL 261134 B2 IL261134 B2 IL 261134B2
- Authority
- IL
- Israel
- Prior art keywords
- carrageenan
- flo
- kappa
- crs
- carrier solution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/731—Carrageenans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016900553A AU2016900553A0 (en) | 2016-02-17 | Compositions and Methods for the Treatment of Sinus Diseases and Disorders | |
| PCT/AU2017/050144 WO2017139854A1 (en) | 2016-02-17 | 2017-02-17 | Compositions and methods for the treatment of sinus disease and disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL261134A IL261134A (en) | 2018-10-31 |
| IL261134B IL261134B (en) | 2022-11-01 |
| IL261134B2 true IL261134B2 (en) | 2023-03-01 |
Family
ID=59624790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL261134A IL261134B2 (en) | 2016-02-17 | 2018-08-13 | Preparations and methods for the treatment of sinus diseases and disorders |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11357791B2 (enExample) |
| EP (1) | EP3416655A4 (enExample) |
| JP (1) | JP2019505538A (enExample) |
| KR (1) | KR20180108811A (enExample) |
| CN (1) | CN108697731A (enExample) |
| AU (1) | AU2017220396B2 (enExample) |
| BR (1) | BR112018016651A2 (enExample) |
| CA (1) | CA3013942C (enExample) |
| HK (1) | HK1258884A1 (enExample) |
| IL (1) | IL261134B2 (enExample) |
| MY (1) | MY200434A (enExample) |
| SG (1) | SG11201806835SA (enExample) |
| WO (1) | WO2017139854A1 (enExample) |
| ZA (1) | ZA201806103B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201806835SA (en) | 2016-02-17 | 2018-09-27 | Ent Tech Pty Ltd | Compositions and methods for the treatment of sinus disease and disorders |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002302448A (ja) * | 2001-04-02 | 2002-10-18 | Shiseido Co Ltd | 皮膚外用剤 |
| WO2012103575A1 (en) * | 2011-02-02 | 2012-08-09 | Ent Technologies Pty Ltd | Compositions and methods for the treatment of nasal passages |
| WO2015082356A1 (en) * | 2013-12-03 | 2015-06-11 | Gerolymatos International S.A. | Ionic aqueous compositions |
| WO2015114622A1 (en) * | 2014-01-28 | 2015-08-06 | Resdevco Research And Development Co. Ltd. | Composition comprising xylitol and cholecalciferol for topical treatment of skin and mucous membranes |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3563194B2 (ja) * | 1996-03-15 | 2004-09-08 | 株式会社ノエビア | 塩化ナトリウム含有ゲル組成物及びその製造方法 |
| JPH11189533A (ja) * | 1997-12-25 | 1999-07-13 | Taisho Pharmaceut Co Ltd | 点眼薬 |
| US6214376B1 (en) * | 1998-08-25 | 2001-04-10 | Banner Pharmacaps, Inc. | Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture |
| US6518244B2 (en) * | 2000-03-09 | 2003-02-11 | Intimax Corporation | Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof |
| CN1491724A (zh) * | 2003-09-02 | 2004-04-28 | 无锡杰西医药科技有限公司 | 一种适用于青光眼治疗的成胶增稠用多糖系统 |
| EP1930015A1 (en) * | 2006-12-05 | 2008-06-11 | Marinomed Biotechnologie GmbH | Use of carrageenan for treating rhinovirus infections |
| US20080317791A1 (en) * | 2007-06-25 | 2008-12-25 | Cp Kelco U.S., Inc. | Kappa Carrageenan |
| JP2011219412A (ja) * | 2010-04-09 | 2011-11-04 | Saisentan Igaku Kenkyusho:Kk | 緑内障の視野改善治療薬 |
| WO2012126777A1 (en) * | 2011-03-18 | 2012-09-27 | Marinomed Biotechnologie Gmbh | Inhibition of neuraminidase activity |
| WO2014123880A1 (en) * | 2013-02-05 | 2014-08-14 | The Population Council, Inc. | Intravaginal ring for the delivery of unique combinations of antimicrobial compositions |
| DE102015110674A1 (de) | 2015-07-02 | 2017-01-05 | Sms Group Gmbh | Umbausystem für einen Elektrolichtbogenofen (EAF) |
| HUE062108T2 (hu) * | 2015-07-14 | 2023-09-28 | Marinomed Biotech Ag | Vírusellenes hatású, orrdugulást megszûntetõ készítmény |
| SG11201806835SA (en) | 2016-02-17 | 2018-09-27 | Ent Tech Pty Ltd | Compositions and methods for the treatment of sinus disease and disorders |
-
2017
- 2017-02-17 SG SG11201806835SA patent/SG11201806835SA/en unknown
- 2017-02-17 HK HK19101357.4A patent/HK1258884A1/zh unknown
- 2017-02-17 EP EP17752579.7A patent/EP3416655A4/en not_active Withdrawn
- 2017-02-17 MY MYPI2018702901A patent/MY200434A/en unknown
- 2017-02-17 JP JP2018542227A patent/JP2019505538A/ja active Pending
- 2017-02-17 BR BR112018016651A patent/BR112018016651A2/pt not_active Application Discontinuation
- 2017-02-17 CN CN201780014521.4A patent/CN108697731A/zh active Pending
- 2017-02-17 CA CA3013942A patent/CA3013942C/en active Active
- 2017-02-17 AU AU2017220396A patent/AU2017220396B2/en active Active
- 2017-02-17 WO PCT/AU2017/050144 patent/WO2017139854A1/en not_active Ceased
- 2017-02-17 US US15/998,565 patent/US11357791B2/en active Active
- 2017-02-17 KR KR1020187025908A patent/KR20180108811A/ko not_active Withdrawn
-
2018
- 2018-08-13 IL IL261134A patent/IL261134B2/en unknown
- 2018-09-12 ZA ZA2018/06103A patent/ZA201806103B/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002302448A (ja) * | 2001-04-02 | 2002-10-18 | Shiseido Co Ltd | 皮膚外用剤 |
| WO2012103575A1 (en) * | 2011-02-02 | 2012-08-09 | Ent Technologies Pty Ltd | Compositions and methods for the treatment of nasal passages |
| WO2015082356A1 (en) * | 2013-12-03 | 2015-06-11 | Gerolymatos International S.A. | Ionic aqueous compositions |
| WO2015114622A1 (en) * | 2014-01-28 | 2015-08-06 | Resdevco Research And Development Co. Ltd. | Composition comprising xylitol and cholecalciferol for topical treatment of skin and mucous membranes |
Also Published As
| Publication number | Publication date |
|---|---|
| US11357791B2 (en) | 2022-06-14 |
| IL261134A (en) | 2018-10-31 |
| HK1258884A1 (zh) | 2019-11-22 |
| AU2017220396A1 (en) | 2018-10-04 |
| KR20180108811A (ko) | 2018-10-04 |
| ZA201806103B (en) | 2019-07-31 |
| AU2017220396B2 (en) | 2022-12-15 |
| EP3416655A1 (en) | 2018-12-26 |
| MY200434A (en) | 2023-12-26 |
| CN108697731A (zh) | 2018-10-23 |
| WO2017139854A1 (en) | 2017-08-24 |
| US20200276226A1 (en) | 2020-09-03 |
| CA3013942C (en) | 2024-03-26 |
| EP3416655A4 (en) | 2019-11-20 |
| CA3013942A1 (en) | 2017-08-24 |
| IL261134B (en) | 2022-11-01 |
| JP2019505538A (ja) | 2019-02-28 |
| BR112018016651A2 (pt) | 2018-12-26 |
| SG11201806835SA (en) | 2018-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Agarwal et al. | Formulation considerations for the management of dry eye disease | |
| Wang et al. | Effect of budesonide transnasal nebulization in patients with eosinophilic chronic rhinosinusitis with nasal polyps | |
| Yang et al. | Pathological collagen targeting and penetrating liposomes for idiopathic pulmonary fibrosis therapy | |
| Weng et al. | Inhalable cardiac targeting peptide modified nanomedicine prevents pressure overload heart failure in male mice | |
| Casale et al. | Hyaluronic acid and upper airway inflammation in pediatric population: A systematic review | |
| IL255452B (en) | Aqueous suspension containing nanoparticles of glucocorticosteroid | |
| IL263341B2 (en) | Stem cell material, compounds and methods of use | |
| IL251769B (en) | Varnicline compound for use as a drug for treating dry eye, increasing tear production and treating eye discomfort and a premebacte preparation containing Varnicline | |
| Zou et al. | Release and actions of inflammatory exosomes in pulmonary emphysema: potential therapeutic target of acupuncture | |
| Chen et al. | Therapeutic nanocoating of ocular surface | |
| CN118236357A (zh) | 一种治疗肺纤维化的雾化吸入纳米脂质体组合物及其制备方法和应用 | |
| Harvey et al. | Local drug delivery | |
| Zuo et al. | Preparation of budesonide-loaded liposomal nanoparticles for pulmonary delivery and their therapeutic effect in OVA-induced asthma in mice | |
| Li et al. | Regeneration of olfactory neuroepithelium in 3-methylindole-induced anosmic rats treated with intranasal chitosan | |
| IL261134B2 (en) | Preparations and methods for the treatment of sinus diseases and disorders | |
| Li et al. | A Stemness‐Enhanced Eye Drop Stimulates Corneal Regeneration via Sustained Release of Versican and Providing Lubricated Substrate | |
| Yao et al. | Intratracheal delivery of macrophage targeted Celastrol-loaded PLGA nanoparticles for enhanced anti-inflammatory efficacy in acute lung injury mice | |
| Su et al. | The effect of doxycycline temperature-sensitive hydrogel on inhibiting the corneal neovascularization induced by BFGF in rats | |
| Ercan et al. | Efficacy of sodium hyaluronate in relieving nasal symptoms of children with intermittent allergic rhinitis: a randomized controlled trial | |
| Altraja et al. | Synthesis of tenascin and laminin beta2 chain in human bronchial epithelial cells is enhanced by cysteinyl leukotrienes via CysLT1 receptor | |
| IL297114A (en) | Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases | |
| Kim et al. | Pulmonary surfactant-based pirfenidone-loaded nanovesicles for inhalation therapy of idiopathic pulmonary fibrosis | |
| Li et al. | Topical cyclodextrin minocycline inclusion complex inhibited the inflammation in blepharitis-related dry eye disease | |
| Deng et al. | Nebulized liposomal co-delivery of nintedanib and tetrandrine for enhanced treatment of pulmonary fibrosis | |
| TWI760996B (zh) | 含有疏水性物質的奈米組成物及其製備方法與用途 |